---
title: "Arvinas anticipates Phase 3 topline results for vepdegestrant in Q1 2025 with commercial preparations underway"
date: "2025-02-11 23:22:39"
summary: "Earnings Call Insights: Arvinas, Inc. (NASDAQ:ARVN) Q4 2024 Management View CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this trial, if successful, will support the company’s first..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Arvinas, Inc. (NASDAQ:[ARVN](https://seekingalpha.com/symbol/ARVN "Arvinas, Inc.")) Q4 2024

### Management View

* CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this trial, if successful, will support the company’s first new drug application and transition into a commercial-stage company.
* Houston highlighted their ongoing collaboration with Pfizer for vepdeg, including plans to initiate two new Phase 3 combination trials in 2025. The first trial will combine vepdeg with Pfizer’s CDK4 inhibitor, atirmociclib, for first-line metastatic breast cancer treatment. The second trial will evaluate vepdeg with a CDK4/6 inhibitor in a second-line setting.
* CFO Andrew Saik reported $59.2 million in Q4 2024 revenue, driven by adjustments from prior periods, and stated cash reserves of over $1 billion, sufficient to fund operations into 2027. He attributed the company’s financial strength to its strategic objectives, including advancing vepdeg programs and early-stage pipeline assets.

### Outlook

* Management plans to release VERITAC-2 topline results in Q1 2025. This trial evaluates vepdeg as a monotherapy in ER-positive/HER2-negative advanced breast cancer patients who have progressed on CDK4/6 inhibitors and endocrine therapies.
* First-line Phase 3 trials for vepdeg and atirmociclib will focus on leveraging Pfizer’s CDK4 inhibitor to potentially differentiate from other CDK4/6 inhibitors. Regulatory discussions and emerging data are expected to finalize trial designs.
* The company also intends to present first-in-human data from ARV-102, its LRRK2 degrader for neurodegenerative diseases, at an upcoming Alzheimer’s and Parkinson’s Disease conference.

### Financial Results

* Revenue for Q4 2024 was $59.2 million, compared to negative $43.1 million in Q4 2023, driven by adjustments in contract revenue estimates.
* Research and development expenses decreased to $83.3 million in Q4 2024 due to the out-licensing of ARV-766. General and administrative expenses rose to $34.1 million, reflecting investments in commercial operations and infrastructure.
* Full-year 2024 revenue reached $263.4 million, up from $78.5 million in 2023, supported by collaborations with partners like Pfizer.

### Q&A

* Derek Archila, Wells Fargo: Asked about TACTIVE-U combination data. Noah Berkowitz responded that vepdeg combinations with ribociclib and abemaciclib are progressing, with data maturation expected to guide next steps.
* Jonathan Miller, Evercore ISI: Inquired about the first-line Phase 3 trial’s gating factors. Berkowitz explained that safety and early efficacy data from the atirmociclib combination would be key, alongside regulatory discussions.
* Tazeen Ahmad, Bank of America: Questioned commercial readiness for vepdeg. Houston confirmed the U.S. commercial team is in place, with Pfizer leading international efforts.

### Sentiment Analysis

* Analysts maintained a cautiously optimistic tone, focusing on the VERITAC-2 readout and combination trial strategies. Questions reflected interest in competitive differentiation and regulatory pathways.
* Management presented a confident outlook but avoided specifics on trial expectations. Houston’s statements conveyed readiness for commercial execution, while Berkowitz emphasized data-driven decision-making for pipeline progression.
* Compared to the prior quarter, management’s tone showed increased urgency and confidence as key milestones approach.

### Quarter-over-Quarter Comparison

* The Q4 2024 call emphasized upcoming topline data for VERITAC-2, whereas Q3 focused on the broader pipeline and initial Phase 3 planning.
* Management provided greater detail on combination trial designs in Q4, particularly with atirmociclib.
* Analysts in Q4 were more focused on competitive positioning and trial readouts, reflecting the proximity to key data releases.
* Financially, Q4 reported higher revenue due to prior-period adjustments, contrasting with Q3’s emphasis on licensing agreements.

### Risks and Concerns

* The VERITAC-2 trial’s outcome is critical, with failure potentially delaying commercialization of vepdeg.
* Competition in the CDK4/6 inhibitor space could limit differentiation for vepdeg combinations.
* Regulatory feedback for first-line and second-line trials remains a potential bottleneck.

### Final Takeaway

Arvinas is poised for a milestone-rich 2025, with the VERITAC-2 topline readout being a pivotal event. The company’s collaboration with Pfizer and robust financial position support its ambitious pipeline, including vepdeg combinations and neurodegenerative disease programs. Management’s focus on strategic execution and differentiation underscores its commitment to advancing innovative treatments in oncology and neuroscience.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/ARVN/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4406373-arvinas-anticipates-phase-3-topline-results-for-vepdegestrant-in-q1-2025-with-commercial)
